Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?

Skedgel, C ORCID: https://orcid.org/0000-0003-4989-8846, Rayson, D and Younis, T (2013) Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer? Annals of Oncology, 24 (7). pp. 1834-40. ISSN 0923-7534

Full text not available from this repository. (Request a copy)

Abstract

In light of clinical uncertainty and the high acquisition costs of trastuzumab, we examined the value for money associated with concurrent or sequential trastuzumab in women with HER-2/neu-positive breast cancer with small node-negative tumours (T1bN0).

Item Type:	Article
Uncontrolled Keywords:	adult,aged,aged 80 and over,antibodies, monoclonal humanized),antineoplastic agents,breast neoplasms,chemotherapy (adjuvant),cost-benefit analysis,female,humans,middle aged,models (economic),neoplasm recurrence (local),neoplasm staging,quality-adjusted life years,receptor (erbb-2),risk,treatment outcome,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Economics Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023)
Depositing User:	Pure Connector
Date Deposited:	21 Jan 2015 12:46
Last Modified:	21 Oct 2022 00:29
URI:	https://ueaeprints.uea.ac.uk/id/eprint/51921
DOI:	10.1093/annonc/mdt069

Actions (login required)

View Item